Category Archives: Genetics

My Genetics 330 Pounds GOAT Ronnie Coleman Once Revealed Secret to Inhuman 0.3 Fat Percentage to Joe Rogan That Helped Him Collect More Mr. Olympia…

Joe Rogan, the veteran UFC color commentator, and eight-time Mr. Olympia Ronnie Coleman, are two of the most prominent names in their respective fields. Interestingly, the duo once came together for over an hour-long chat in 2020 on the famous Joe Rogan Experience podcast hosted by the UFC color commentator.

ADVERTISEMENT

Article continues below this ad

During the episode, the duo thoroughly talked about Colemans life, including his records, diet, injuries, and more. At one point during the conversation, Rogan asked the former IFBB professional about his body fat percentage while he was competing.

ADVERTISEMENT

Article continues below this ad

The bodybuilding legend told the JRE host he had a 0.33 percent at that time, which quite stunned the latter. I was point three, three, Coleman said. Point three, three, what does that mean? Is that less than three percent? Rogan replied in shock.

Thats less than half a percent, the former Mr. Olympia further admitted. At this point, the MMA enthusiast was in disbelief. So he further asked, Point three, three like what!! How does a human get that low?

I got to attribute to my genetics, Coleman replied. Further on, Rogan asked about his offseason body fat number. About three percent, Coleman answered. The veteran UFC color commentator is a fitness enthusiast and maintains good shape by working out regularly. Thus, he has enough knowledge about bodybuilding. However, he was still shocked by Colemans statement.

So he further asked, Three was that high? To which the 8-time consecutive winner of Mr. Olympia replied, Thats the highest I am 330 pounds at that, though.

Professional bodybuilders are famous for having a very less body fat percentage. They cut down even more fat before their competition by cutting down water, sugar, fatty foods, salt, and more.

Coleman claimed about having 0.33 percent body fat during competition. His assertions, however, were refuted by physical medicine and rehabilitation specialist Dr. Brian Sutterer, who said it was inhumanely impossible.

ADVERTISEMENT

Article continues below this ad

DIVE DEEPER

Rare Photo Shows Jacked Joe Rogan Next to 300 Lbs Ronnie Coleman, Who Won MoreMr. Olympia Titles Than Arnold Schwarzenegger

3 days ago

In a YouTube video, Dr. Sutterer said it is necessary to maintain three to five percent of body fat, as fats are vital to absorb vitamins, regulate hormones, and regulate body temperature.

However, Dr. Sutterer further added that the machines that are used to measure body fat percentage arent 100 percent accurate. This might have been the case with the legendary bodybuilder, as per Dr. Sutterer.

ADVERTISEMENT

Article continues below this ad

What are your thoughts on Dr. Sutterers explanations? What do you guys think about Colemans statement on Rogans podcast? Let us know in the comments section below.

WATCH THIS STORY: 5 Best Joe Rogan Memes Following Leon Edwards Brutal Knockout Victory Over Kamaru Usman at UFC 278

Read more from the original source:
My Genetics 330 Pounds GOAT Ronnie Coleman Once Revealed Secret to Inhuman 0.3 Fat Percentage to Joe Rogan That Helped Him Collect More Mr. Olympia...

Fulgent Genetics’s Return On Invested Capital Insights – Benzinga

Pulled from Benzinga Pro data, Fulgent Genetics FLGT posted Q2 earnings of $11.10 million, an increase from Q1 of 92.77%. Sales dropped to $125.34 million, a 60.86% decrease between quarters. Fulgent Genetics earned $153.56 million, and sales totaled $320.27 million in Q1.

Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly pre-tax profit relative to invested capital by a business. Generally, a higher ROIC suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Fulgent Genetics posted an ROIC of 1.18%.

It is important to keep in mind that ROIC evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

ROIC is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROIC shows Fulgent Genetics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of invested capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Fulgent Genetics, the positive return on invested capital ratio of 1.18% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Fulgent Genetics reported Q2 earnings per share at $0.78/share, which beat analyst predictions of $0.73/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Follow this link:
Fulgent Genetics's Return On Invested Capital Insights - Benzinga

Could Genetics Be the Key to Never Getting the Coronavirus? – The Atlantic

Last Christmas, as the Omicron variant was ricocheting around the United States, Mary Carrington unknowingly found herself at a superspreader eventan indoor party, packed with more than 20 people, at least one of whom ended up transmitting the virus to most of the gatherings guests.

After two years of avoiding the coronavirus, Carrington felt sure that her time had come: Shed been holding her great-niece, who tested positive soon after, and she was giving me kisses, Carrington told me. But she never caught the bug. And I just thought, Wow, I might really be resistant here. She wasnt thinking about immunity, which she had thanks to multiple doses of a COVID vaccine. Rather, perhaps via some inborn genetic quirk, her cells had found a way to naturally repel the pathogens assaults instead.

Carrington, of all people, understood what that would mean. An expert in immunogenetics at the National Cancer Institute, she was one of several scientists who, beginning in the 1990s, helped uncover a mutation that makes it impossible for most strains of HIV to enter human cells, rendering certain people essentially impervious to the pathogens effects. Maybe something analogous could be safeguarding some rare individuals from SARS-CoV-2 as well.

Read: America is running out of COVID virgins

The idea of coronaviral resistance is beguiling enough that scientists around the world are now scouring peoples genomes for any hint that it exists. If it does, they could use that knowledge to understand whom the virus most affects, or leverage it to develop better COVID-taming drugs. For individuals who have yet to catch the contagiona fast-dwindling proportion of the populationresistance dangles like a superpower that people cant help but think they must have, says Paula Cannon, a geneticist and virologist at the University of Southern California.

As with any superpower, though, bona fide resistance to SARS-CoV-2 infection would likely be very rare, says Helen Su, an immunologist at the National Institutes of Allergy and Infectious Disease. Carringtons original hunch, for one, eventually proved wrong: She recently returned from a trip to Switzerland and found herself entwined with the virus at last. Like most people who remained unscathed until recently, Carrington had done so for two and a half years through a probable combination of vaccination, cautious behavior, socioeconomic privilege, and luck. Its entirely possible that inborn coronavirus resistance may not even existor that it may come with such enormous costs that its not worth the protection it theoretically affords.

Of the 1,400 or so viruses, bacteria, parasites, and fungi known to cause disease in humans, Jean-Laurent Casanova, a geneticist and an immunologist at Rockefeller University, is certain of only three that can be shut out by bodies with one-off genetic tweaks: HIV, norovirus, and a malaria parasite.

The HIV-blocking mutation is maybe the most famous. About three decades ago, researchers, Carrington among them, began looking into a small number of people who we felt almost certainly had been exposed to the virus multiple times, and almost certainly should have been infected, and yet had not, she told me. Their superpower was simple: They lacked functional copies of a gene called CCR5, which builds a cell-surface protein that HIV needs in order to hack its way into T cells, the viruss preferred human prey. Just 1 percent of people of European descent harbor this mutation, called CCR5-32, in two copies; in other populations, the trait is rarer still. Even so, researchers have leveraged its discovery to cook up a powerful class of antiretroviral drugs, and purged the virus from two people with the help of 32-based bone-marrow transplantsthe closest that medicine has come to developing a functional HIV cure.

The stories with those two other pathogens are similar. Genetic errors in a gene called FUT2, which pastes sugars onto the outsides of gut cells, can render people resistant to norovirus; a genomic tweak erases a protein called Duffy from the walls of red blood cells, stopping Plasmodium vivax, one of several parasites that causes malaria, from wresting its way inside. The Duffy mutation, which affects a gene called DARC/ACKR1, is so common in parts of sub-Saharan Africa that those regions have driven rates of P. vivax infection way down.

In recent years, as genetic technologies have advanced, researchers have begun to investigate a handful of other infection-resistance mutations against other pathogens, among them hepatitis B virus and rotavirus. But the links are tough to definitively nail down, thanks to the number of people these sorts of studies must enroll, and to the thorniness of defining and detecting infection at all; the case with SARS-CoV-2 will likely be the same. For months, Casanova and a global team of collaborators have been in contact with thousands of people from around the world who believe they harbor resistance to the coronavirus in their genes. The best candidates have had intense exposures to the virussay, via a symptomatic person in their homeand continuously tested negative for both the pathogen and immune responses to it. But respiratory transmission is often muddied by pure chance; the coronavirus can infiltrate people silently, and doesnt always leave antibodies behind. (The team will be testing for less fickle T-cell responses as well.) People without clear-cut symptoms may not test at all, or may not test properly. And all on its own, the immune system can guard people against infection, especially in the period shortly after vaccination or illness. With HIV, a virus that causes chronic infections, lacks a vaccine, and spreads through clear-cut routes in concentrated social networks, it was easier to identify those individuals whom the virus had visited but not put down permanent roots within, says Ravindra Gupta, a virologist at the University of Cambridge. SARS-CoV-2 wont afford science the same ease of study.

Read: Is BA.5 the reinfection wave?

A full analogue to the HIV, malaria, and norovirus stories may not be possible. Genuine resistance can manifest in only so many ways, and tends to be born out of mutations that block a pathogens ability to force its way into a cell, or xerox itself once its inside. CCR5, Duffy, and the sugars dropped by FUT2, for instance, all act as microbial landing pads; mutations rob the bugs of those perches. If an equivalent mutation exists to counteract SARS-CoV-2, it might logically be found in, say, ACE2, the receptor that the coronavirus needs in order to break into cells, or TMPRSS2, a scissors-like protein that, for at least some variants, speeds the invasive process along. Already, researchers have found that certain genetic variations can dial down ACE2s presence on cells, or pump out junkier versions of TMPRSS2hints that there could be tweaks that further strip away the molecules. But ACE2 is very important to blood-pressure regulation and the maintenance of lung-tissue health, said Su, of NIAID, whos one of many scientists collaborating with Casanova to find SARS-CoV-2 resistance genes. A mutation that keeps the coronavirus out might very well muck around with other aspects of a persons physiology. That could make the genetic tweak vanishingly rare, debilitating, or even, as Gupta put it, not compatible with life. People with the CCR5-32 mutation, which halts HIV, are basically completely normal, Cannon told me, which means HIV kind of messed up in choosing CCR5. The coronavirus, by contrast, has figured out how to exploit something vital to its hostan ingenious invasive move.

The superpowers of genetic resistance can have other forms of kryptonite. A few strains of HIV have figured out a way to skirt around CCR5, and glom on to another molecule, called CXCR4; against this version of the virus, even people with the 32 mutation are not safe. A similar situation has arisen with Plasmodium vivax, which we do see in some Duffy-negative individuals, suggesting that the parasite has found a back door, says Dyann Wirth, a malaria researcher at Harvards School of Public Health. Evolution is a powerful strategyand with SARS-CoV-2 spewing out variants at such a blistering clip, I wouldnt necessarily expect resistance to be a checkmate move, Cannon told me. BA.1, for instance, conjured mutations that made it less dependent on TMPRSS2 than Delta was.

Read: The BA.5 wave is what COVID normal looks like

Still, protection doesnt have to be all or nothing to be a perk. Partial genetic resistance, too, can reshape someones course of disease. With HIV, researchers have pinpointed changes in groups of so-called HLA genes that, through their impact on assassin-like T cells, can ratchet down peoples risk of progressing to AIDS. And a whole menagerie of mutations that affect red-blood-cell function can mostly keep malaria-causing parasites at baythough many of these changes come with a huge human cost, Wirth told me, saddling people with serious clotting disorders that can sometimes turn lethal themselves.

With COVID-19, too, researchers have started to home in on some trends. Casanova, at Rockefeller, is one of several scientists who has led efforts unveiling the importance of an alarm-like immune molecule called interferon in early control of infection. People who rapidly pump out gobs of the protein in the hours after infection often fare just fine against the virus. But those whose interferon responses are weak or laggy are more prone to getting seriously sick; the same goes for people whose bodies manufacture maladaptive antibodies that attack interferon as it passes messages between cells. Other factors could toggle the risk of severe disease up or down as well: cells ability to sense the virus early on; the amount of coordination between different branches of defense; the brakes the immune system puts on itself, so it does not put the hosts own tissues at risk. Casanova and his colleagues are also on the hunt for mutations that might alter peoples risk of developing long COVID and other coronaviral consequences. None of these searches will be easy. But they should be at least simpler than the one for resistance to infection, Casanova told me, because the outcomes theyre measuringserious and chronic forms of diseaseare that much more straightforward to detect.

If resistance doesnt pan out, that doesnt have to be a letdown. People dont need total blockades to triumph over microbesjust a defense thats good enough. And the protection were born with isnt all the leverage weve got. Unlike genetics, immunity can be easily built, modified, and strengthened over time, particularly with the aid of vaccines. Those DIY defenses are probably what kept Carringtons case of COVID down to a mild course, she told me. Immune protection is also a far surer bet than putting a wager on what we may or may not inherit at birth. Better to count on the protections we know we can cook up ourselves, now that the coronavirus is clearly with us for good.

Read more from the original source:
Could Genetics Be the Key to Never Getting the Coronavirus? - The Atlantic

Life and ethics in an ‘era of genetics’ – DW (English)

When we talk about genetics, we often see visions of superhumans people whose DNA has been altered to enhance their abilities, allowing them to outperform others and survive multiple diseases while also having conventionalgood looks, like "best versions" of humanity.

But those visions can be true of dystopian literature or in the plots of clich science fiction movies, and less true for reality.

George Church, a world-leading geneticist, says the idea of creating superhumans is far from what he sees as the future of genetics.

"There's a misunderstanding that you could have a perfect human or even a superhuman. It's often a trade-off," Church told DW. "When you gain something, you lose something. The features that you like about a bicycle are not true for a race car or a jet."

Church has worked in genetics for decades. He was one of the first scientists to sequence the human genome, a method that deciphers the genetic material found in an organism. He also pioneered the development of genome-engineering.

Genome-engineering goes by a few names. Some call it genetic engineering, others call it genome or gene editing.

Some call it a technology, and others refer to it as though it were a pair of scissors you hold in your hands. And in a sense that image works: We can use gene editing techniques to cut out genes that, for example, carry hereditary diseases.

In fact, the technology allows us to add, remove or alter genetic material found in any organism's DNA that complex molecule that contains the unique building blocks of every living thing.

Gregor Mendel first discovered the fundamentals of inheritance in 1865, through experiments on crossbreeding plants. Those experiments led to what we now call genetics. And oh how the field has progressed.

Speaking from his Harvard University lab, Church said we were living in an "era of genetics."

Mendel's early discoveries have allowed scientists to sequence genomes including that of viruses like SARS-CoV-2 and identify the genes that are responsible for more than 5,000 rare diseases.

They have given us a better understanding of how genes function, and that has raised the promise of improving diagnoses and therapies for illnesses. Church has focused on using genetics to reverse the process of aging.

Genetics are also used in the science of "de-extinction" a famous example being the attempt to bring the mammoth back to life.

Church and other geneticists hope to reverse the effects of age-related chronic diseases, such as diabetes, cognitive degradation and heart diseases. They hope to prevent diseases that cause poverty.

"A lot of people are kept in poverty because they have to spend much of their time on bad nutrition and fighting infectious diseases. [With genetic research], we could get a virtuous cycle rather than a vicious cycle. And that's very exciting to me," said Church.

Gene editing rewrites DNA to treat genetic or acquired diseases

"[We might also need] to get off the planet for reasons that are not human, like asteroids, solar flares, super volcanoes, things like that. That may require some powerful medicine, including genetic medicine, to make us resistant to radiation and low gravity and so on," he said.

These future visions come with an array of ethical and philosophical questions, which some experts say we have yet to address.

Take, for instance, the question of what makes us human and who is allowed to decide which genes we change.

"The issue with gene editing and gene therapy has always been [the future] generations," said Jan Witkowski, a professor at the Graduate School of Biological Sciences at Cold Spring Harbor, New York, in the US. "If the gene therapy alters an egg, then that change is inherited through the generations."

And those future generations have no say on whether they want that change to be made.

The field of genetics has allowed scientists to develop personalized medicine, where treatments can be tailored to an individual's specific condition. We have also built huge repositories of genetic data.

But some scientists argue that these repositories are unrepresentative of the global population. With nearly 90% of the genome data currently available coming from people with European ancestry, the data lacks diversity.

This disparity could result in underrepresented populations missing out on the benefits of genetic research.

Genetics is also still very expensive. Church said the technology may get more affordable, like the Internet, and to some extent water and education, but none of those "are truly equitable," he said.

"The only technology I've identified that's truly equally distributed, meaning that nobody on the planet has to pay a penny for it, is smallpox," Church said. "That's because it's extinct: We no longer have to develop and deploy vaccines and drugs [against smallpox]. And that could be done for a whole variety of infectious diseases [with genetics]."

Edited by: Zulfikar Abbany

Go here to see the original:
Life and ethics in an 'era of genetics' - DW (English)

Are Allergies Hereditary? The Genetics of Allergies, Explained. – Fatherly

Introducing your kid to new foods should be a fun experience, but theres a hidden danger that can make taste-testing a disaster: anaphylaxis, or a severe allergic reaction. Many allergies are mild and only result in occasional sniffles, but others can be fatal. With allergies becoming more common over the past 50 years and today affecting upwards of 40% of the population worldwide, parents may wonder where allergies come from and if theyre responsible for passing down allergies to their children, or if theres a way to prevent their kids from developing allergies. In other words, are allergies hereditary?

Children can inherit the tendency to be allergic a characteristic known as atopy from their parents, according to Richard Wasserman, M.D., Ph.D., medical director of Pediatric Allergy and Immunology at the Medical City Children's Hospital in Dallas, Texas. Just as each childs hair color is uniquely positioned on a spectrum from flaxen blond to coal black and determined by the complex interactions of more than 120 genes, so too do allergies develop when a host of different gene patterns combine in children.

Children with allergic parents have between a 50% to 80% chance of developing allergies. And maternal allergies are more likely than paternal allergies to lead to the child inheriting allergies. However, its not like a mothers allergies to penicillin will be directly inherited by her child, Wasserman says. Although we know significantly more about the genetics of allergy today than we did even 10 years ago, it is enormously complex and we still only have a limited understanding, he says.

There are often many genes at play that can be triggered by various allergens in the childs environment, he explains. For example, people may inherit the tendency to be allergic from their parents, but then develop pollen allergies specifically to the regional pollen in their environment.

People inherit the ability to be allergic, but they dont inherit what theyre allergic to, Wasserman says. In the same family, there can be people who are allergic to cats and other people who are allergic to peanuts and other people who have hives, and some people who have more than one of those problems.

The effects of the environment on developing allergies is often mediated by epigenetic modifications, which are changes to DNA, but not to genes themselves. Epigenetic modifications do, however, change how how the body reads those genes. Epigenetic changes are known to play a role in hay fever, food allergies, asthma, eczema, and other allergy disorders.

Sparse studies have linked individual genes with specific allergens. For example, gene variants in the human lupicize antigen (HLA) complex the same region that can help determine genetic compatibility of transplants have been linked to peanut allergies. A recent study linked mutations on the filaggrin gene related to the skins barrier and moisturization to milk and egg allergies. And scientists have long thought asthma is associated with several different genes related to the immune system.

Allergens are also connected to one another through a process called the allergic march, in which many children first develop eczema, followed by food allergy, and then asthma and nasal allergies. All of this occurs within the first six years of life.

The allergic march is thought to occur as a result of certain gene mutations and environmental factors, but its unclear why some children will outgrow certain allergies and others continue along the march. Luckily, it is possible for parents to disrupt the allergic march by treating problems like eczema as they come up, Wasserman says.

There are no foolproof ways to prevent a child from developing allergies, but there are ways to lower the odds. Exposing children to certain allergens in specific ways has been shown to reduce their risk of developing an allergy to that substance later on.

For example, some studies show pet dogs decrease the risk of asthma when introduced in the first year of life, and that children who grow up in rural farmlands with lots of animals have a lower risk of developing allergies than children who grow up in urban cities. But owning a cat has been shown to increase the risk of cat allergy in countries without many of these animals and decrease it in countries like the U.S. that have a lot of cats, so introducing the allergen early may not always be helpful. Its not a straightforward relationship.

Similarly, when it comes to food allergies, the American Academy of Pediatrics currently recommends introducing so-called problem foods such as milk, eggs, and peanut butter around four months, once a child is accustomed to eating solid foods, to reduce the risk of developing an allergy to them.

However, kids who are exposed topically, or through the skin, to foods like peanuts have been shown to have a higher risk of developing allergies. Food sensitization is especially likely to develop when children are exposed through skin damaged by eczema, Wasserman says. Thats why treating eczema and maintaining good skin care is so important, he adds.

A childs pediatrician may recommend oral immunotherapy, a process in which doctors feed allergic children portions of food allergens to build up a tolerance. Once children are a bit older, doctors may also recommend using allergy shots to treat them, Wasserman says.

One theory regarding why allergies are becoming more prevalent these days, called the hygiene hypothesis, stems from the idea that exposure to microbes and germs decreases the risk of allergies. The idea is that while sanitizing can be helpful in preventing the spread of harmful germs that spread infections like COVID-19, over-hygienic environments also remove non-harmful germs that build up the immune system.

If there is exposure to germs that are not disease-causing, thats how the immune system develops, Wasserman says. Being in an environment devoid of germs increases a lot of problems, but it probably also increases allergy.

Not subscribed to Fatherlys newsletter yet? Were not mad, just disappointed.

Follow this link:
Are Allergies Hereditary? The Genetics of Allergies, Explained. - Fatherly

My Insights to Cancer Genetics After More Than 20 Years of Brain Tumor Survival – Curetoday.com

I never knew cancer would enter my life. Nobody in my family had cancer, and I did not think about the disease. I was in my early 20s and excited for my future.

Diagnosed with a brain tumor on March 18, 1998, parts of me went into a dark frozen place. I quickly had to find some ways to perform research to find the best course of action. Since then, I have had three awake brain surgeries in 1998, 2011 and 2013, radiation and chemotherapy in 2014, and an immunotherapy clinical trial with a dendritic cell-based vaccine the same year. I continued to have MRIs and other tests regularly that I still do.

Early in my cancer journey, I learned about complementary and alternative therapies. I wanted to prevent the brain tumor and support my wellness. Over several years, I focused on integrative cancer care for the whole person to improve quality of life and survival.

Research says that many cancers link to lifestyle factors and the environment. As a result, I studied and used new strategies that I felt would be optimal to live better and feel longer: a healthy organic diet, exercise, stress reduction, meditation, massage, acupuncture, a cleaner environment, the mind-body connection and other approaches have shown benefits to cancer patients. Ive done much more than that, yet an unexpected problem emerged.

In 2018, I felt tremendously grateful to become a 20-year brain tumor survivor. But my body wasnt perfect, including some funks in my gut. I saw two gastrointestinal doctors who ultimately said to get a colonoscopy and endoscopy. At that point, the U.S. government recommended a colonoscopy starting at 50 years, but being 45 years old, I did it anyway. The results showed almost 30 large polyps and 100 smaller polyps.

Moreover, I had to meet with a genetic counselor. The simple blood test showed I had mutations in the MUTYH gene from family history. This hereditary condition is characterized by developing multiple colorectal adenomatous and increased colorectal cancer risk. Due to my mutation, it is vital to get colonoscopies and endoscopies regularly. The report also noted different cancer types as possibilities.

The National Cancer Institute says that 5 to 10% of cancer diagnoses are related to genetics. Some research has shown that it is slightly higher. Regardless, eachindividual needs to address and track their uniquesituation.

Practitioners may not talk about genetics unless two family members have had cancer. In 1998 when diagnosed, nobody in my family had cancer. It only surfaced when my grandma was diagnosed with pancreatic cancer and died two weeks later in 2010, and my brother was diagnosed with an acoustic neuroma in 2018. They were diagnosed 12 and 20 years, respectively, after my brain tumor diagnosis.

I know genetic cancers are rare, but both patients and practitioners must explore and track the situation.

Through an ultrasound ordered by my OBGYN a few years ago, I learned that I needed to get endometrial surgery to remove polyps. That happened in 2020 and 2022. The pathology report from the endometrial surgery this year showed I had a precancerous lesion. Details said I needed to get a hysterectomy, which occurred in June of 2022. I am feeling vibrantlywell while still taking care of my body post-surgery.

I know challenges can become opportunities, and adversity can be turned into actions. In my path, Ive learned that understanding the past, addressing the present and engaging wellness for the future is essential for thriving. Indeed, even though the unexpected can emerge, its helpful to have a plan, team and self-care strategies blended with gratitude and resilience. I wish you optimal health and healing.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Read more here:
My Insights to Cancer Genetics After More Than 20 Years of Brain Tumor Survival - Curetoday.com

OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ…

ROCKVILLE, Md., July 26, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc.(Nasdaq: OPGN, OpGen) announced today that its subsidiary Ares Genetics GmbH(Ares Genetics), which strives to become a leader in bacterial genomics and the Artificial Intelligence (AI)-powered prediction of antimicrobial resistance (AMR), and the Belgian National Reference Centre for invasive S. pneumoniae at the Universitair Ziekenhuis Leuven (UZ Leuven) have entered into a collaboration agreement to jointly evaluate computational tools developed by Ares Genetics for the identification and characterization of Streptococcus pneumoniae for diagnostic purposes.

AMR is a serious threat to public health. Over five years, the estimated number of annual deaths that might have been prevented by effective antimicrobial therapy has grown by 81% to approximately 1.27 million deaths.1,2 Among other AMR pathogens, the U.S. Center of Disease Control has classified drug-resistant Streptococcus pneumoniae as a serious antibiotic resistant threat on its website.3

Ares Genetics and UZ Leuven aim to employ machine learning tools for antibiotic susceptibility testing of Streptococcus pneumoniae directly from whole genome sequencing data. The AI-based wgsAST technology developed by Ares Genetics4 relies on predictive models which are trained on ARESdb, a proprietary AMR knowledgebase and collection of pathogen genome data and associated data on phenotypic antibiotic susceptibility and resistance.

We are excited to jointly demonstrate and advance the utility of antibiotic susceptibility prediction directly from genome data. AMR in respiratory pathogens, including in Pneumococci, is a serious healthcare threat, said Dr. Arne Materna, CEO of Ares Genetics. We welcome the collaboration with the experts at UZ Leuven tasked with the national surveillance of Streptococcus pneumoniae. Partnerships with national reference and public health laboratories allow us to aggregate current data on AMR in key pathogens, to further enrich our ARESdb, and in turn to deploy an up-to-date AI for wgsAST where it matters.

The collaboration with UZ Leuven follows after another collaboration agreement between Ares Genetics and an unnamed international commercial reference laboratory had been announced in 2021.

Ares Genetics plans to expand ARESdb with data collected at the national reference center, to develop and deploy wgsAST models for Streptococcus pneumoniae, and to jointly evaluate their performance compared to conventional methods. In return for access to genome and AMR phenotype data, Ares Genetics will deploy AREScloud at the National Reference Centre for invasive S. pneumoniae at UZ Leuven. AREScloud is a commercially available, user-friendly bioinformatics web application for pathogen detection, typing, AMR characterization and outbreak analysis. Unlike other commercial solutions, AREScloud draws on ARESdb to provide rich information on AMR and to offer unique wgsAST capabilities to its users.

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGens product portfolio includes Unyvero, Acuitas AMR Gene Panel and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit http://www.opgen.com.

Forward-Looking Statements

This press release includes statements regarding OpGens subsidiary Ares Genetics GmbHs collaboration agreement with the Belgian National Reference Center at UZ Leuven. These statements and other statements regarding OpGens future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the continued impact of COVID-19 on the Companys operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen:Oliver SchachtPresident and CEOInvestorRelations@opgen.com

OpGen Press Contact:Matthew BretziusFischTank Marketing and PR matt@fischtankpr.com

OpGen Investor Contact:Alyssa FactorEdison Groupafactor@edisongroup.com

1 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext2 https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf3 https://www.cdc.gov/drugresistance/biggest-threats.html#pne4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315026/

See original here:
OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ...

Genetic Testing for Women: What You Need to Know | Health Hive – Health Hive

Over the last quarter century, the advancement of DNA technology allowed physicians and scientists to make considerable advances with medical testing.

Using this new knowledge as a method of screening allows providers to get a better sense of who might have an increased risk of developing certain health conditions. This testing does not determine if a patient has developed or will develop a particular condition, but can determine who might be at substantially increased risk and influence medical management.

Kim Provenzano, NP, is an Advanced Practice Nurse in Genetics at Lipson Cancer Institute with Rochester Regional Health and has 25 years of experience with genetic testing for breast and gynecologic cancers, as well as cardiac conditions.

At Lipson Cancer Institute, genetic testing is offered for a variety of inherited syndromes. This includes but is not limited to:

Identifying at-risk women through the use of genetic testing allows us to create individualized medical interventions that can lead to early detection, prevention, and better quality of life for both our patients and their families, Provenzano said.

Most patients arriving at Lipson Cancer Institute are referred by their providers, whether primary care, cardiology, oncology, radiation, urology, or OBGYN.

Once a patient arrives at their appointment, they will begin genetic counseling with a provider. Genetic counseling focuses on a patients family history of disease and includes a risk assessment. The assessment will include:

Once all of this information is documented, providers will perform a risk calculation to determine if genetic testing would be helpful to the patient.

Based on the results of the assessment and initial appointment, providers will go through the process of informed consent a conversation in which the patient is counseled regarding the benefits, limitations and potential alternatives of genetic testing and is given the opportunity to make an informed decision as well as ask questions.

Genetic testing is conducted by collecting a blood or saliva sample from a patient, depending on the type of test being performed. The sample is then sent to an outside laboratory to be tested. The time between sample collection and results varies based on the type of test being performed.

Providers with Lipson Cancer Institute utilize multi-gene panel testing, which can encompass as many 90 genes in a single test. This technique allows providers to assess a patients risk for many different types of cancer all at once.

If genetic testing identifies a patient as being at increased risk for a particular type of condition, providers are able to connect them to the specialists who are best equipped to help. This may include:

We find patients who have genetic testing done are less anxious, and feel more reassured and empowered to make better health care decisions, Provenzano said. The knowledge they receive allows them to inform other family members about potential risk and seek appropriate medical management. Its a positive thing in most cases.

The Lipson Cancer Institute provides a myriad of professional and medical services that help patients and their families address the implications of increased risk for certain health conditions. Cancer risk assessment and genetic testing services are offered at all of Lipson Cancer Institutes locations. Visit the link below or call (585) 922-6DNA (362).

Follow this link:
Genetic Testing for Women: What You Need to Know | Health Hive - Health Hive

SOPHiA GENETICS to Participate in Canaccord Genuity 42nd Annual Growth Conference – StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

BOSTON and LAUSANNE, Switzerland, July 29, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, announced today Chief Financial Officer, Ross Muken, will attend and be a panelist at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at the InterContinental Hotel in Boston, MA, United States.

Ross will join other industry leaders for the panel Leveraging Omics-Based Data and Analytics to Advance Precision Health to the Next Level, starting at 9:30 a.m. EST.

A live webcast and replay of the session will be available on the investor relations section of the SOPHiA GENETICS website at https://ir.sophiagenetics.com.

About SOPHiA GENETICSSOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM Platform and related solutions, products and services are currently used by more than 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers.

Investor Contact:Jennifer PottageHead of Investor Relations[emailprotected]

Media Contact:Don GranesePublic Relations[emailprotected]

More:
SOPHiA GENETICS to Participate in Canaccord Genuity 42nd Annual Growth Conference - StreetInsider.com